Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF30HL)

Drug Name
Zarnestra Drug Info
Synonyms
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Chronic myelogenous leukaemia 2A20.0 Phase 2 [2]
Human papillomavirus infection 1A9Y Phase 2 [2]
Myelodysplastic syndrome 2A37 Phase 2 [2]
Peripheral T-cell lymphoma 2A90.C Phase 2 [2]
Colorectal cancer 2B91.Z Phase 1/2 [3]
Pancreatic cancer 2C10 Phase 1/2 [3]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
159324
ChEBI ID
CHEBI:141969
CAS Number
CAS 192185-72-1
TTD Drug ID
DMF30HL
VARIDT Drug ID
DR00414

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Farnesyl protein transferase (Ftase)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lonafarnib DMGM2Z6 Hutchinson-Gilford progeria syndrome LD2B Approved [9]
L-778123 DMWSC5L Lymphoma 2A80-2A86 Phase 1 [10]
GGTI-2418 DM8U23L Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
BMS214662 DM5M48F Non-small-cell lung cancer 2C25.Y Phase 1 [12]
L-745631 DM4UP7R Solid tumour/cancer 2A00-2F9Z Terminated [13]
ABT-839 DM4UN9A Non-small-cell lung cancer 2C25.Y Terminated [14]
MANUMYCIN A DM1SWOY N. A. N. A. Terminated [15]
SCH-44342 DMUL4VX N. A. N. A. Terminated [16]
RPR-113829 DMJ63GW N. A. N. A. Terminated [17]
RPR-114334 DMAIJT6 N. A. N. A. Terminated [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Geranyltranstransferase (FDPS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [18]
Minodronate DM50PMY Osteoporosis FB83.0 Approved [19]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [18]
Alendronate DMY2KX9 Bone Paget disease Approved [18]
Pamidronate DMB4AVP Bone Paget disease Approved [20]
Incadronate DM3DSVJ Hypercalcaemia 5B91.0 Approved [21]
Risedronate DM5FLTY Bone Paget disease Approved [22]
NERIDRONIC ACID DMMPG5V Bone disease FC0Z Approved [23]
GERANYLGERANYL DIPHOSPHATE DMJZ0AM Discovery agent N.A. Investigative [24]
ISOPENTENYL PYROPHOSPHATE DMTU05Y Discovery agent N.A. Investigative [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By GTPase HRas (HRAS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [25]
Selenium DM25CGV N. A. N. A. Approved [26]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [27]
Quercetin DM3NC4M Obesity 5B81 Approved [28]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [29]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [30]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [31]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [32]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [33]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Granulocyte-macrophage colony-stimulating factor (CSF2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [35]
Quercetin DM3NC4M Obesity 5B81 Approved [36]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [37]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [38]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [39]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [40]
Testosterone DM7HUNW Hot flushes GA30 Approved [41]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [42]
Acetylcholine DMDF79Z Cataract 9B10 Approved [43]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By GTP-binding protein Rheb (RHEB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [45]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [46]
Lonafarnib DMGM2Z6 Hutchinson-Gilford progeria syndrome LD2B Approved [7]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [47]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [48]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [49]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [50]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [7]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [51]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [53]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [54]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [55]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [56]
Cepharanthine DM9Y5JB N. A. N. A. Approved [57]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [58]
Clozapine DMFC71L Schizophrenia 6A20 Approved [59]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [60]
Trifluoperazine DMKBYWI Anxiety Approved [61]
Olanzapine DMPFN6Y Bipolar depression Approved [59]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Farnesyl protein transferase (Ftase) TTXQKM3 FNTA_HUMAN; FNTB_HUMAN Modulator [4]
Geranyltranstransferase (FDPS) TTIKWV4 FPPS_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Drug Response [5]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Gene/Protein Processing [6]
GTP-binding protein Rheb (RHEB) OTFLTSEC RHEB_HUMAN Gene/Protein Processing [7]
GTPase HRas (HRAS) OTWQN0DP RASH_HUMAN Biochemical Pathways [8]

References

1 ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
4 Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500.
5 Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs. 2004 Aug;22(3):285-9.
6 Genetic disruption of the PI3K regulatory subunits, p85, p55, and p50, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. Haematologica. 2012 Jul;97(7):1042-7. doi: 10.3324/haematol.2011.046896. Epub 2012 Feb 7.
7 Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Lett. 2010 Nov 1;297(1):117-25. doi: 10.1016/j.canlet.2010.05.004.
8 Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun 15;105(12):4759-66. doi: 10.1182/blood-2004-11-4307. Epub 2005 Feb 22.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10 Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
11 Company report (Prescient)
12 Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604.
13 Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
14 Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62.
15 A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6.
16 Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem. 1999 Jun 17;42(12):2125-35.
17 Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
19 Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64.
20 Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24.
21 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
22 Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
23 Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
24 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
25 Profiles of antioxidant/electrophile response element (ARE/EpRE) nuclear protein binding and c-Ha-ras transactivation in vascular smooth muscle cells treated with oxidative metabolites of benzo[a]pyrene. Biochem Pharmacol. 2000 Nov 1;60(9):1285-96.
26 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
27 Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer. 2008;60(3):389-400.
28 Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer. 2000 Feb 1;85(3):438-45.
29 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
30 A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
31 Poly(ADP-ribosyl)ation enhances H-RAS protein stability and causes abnormal cell cycle progression in human TK6 lymphoblastoid cells treated with hydroquinone. Chem Biol Interact. 2015 Aug 5;238:1-8. doi: 10.1016/j.cbi.2015.05.019. Epub 2015 Jun 3.
32 Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol. 2005 Sep;130(6):912-25. doi: 10.1111/j.1365-2141.2005.05696.x.
33 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
34 The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
35 Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: a simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001 Jun;26(2):85-93. doi: 10.1016/s0923-1811(00)00165-1.
36 Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 2000 Apr;30(4):501-8. doi: 10.1046/j.1365-2222.2000.00768.x.
37 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
38 Altered cytokine profiles of human retinal pigment epithelium: oxidant injury and replicative senescence. Mol Vis. 2013;19:718-28. Epub 2013 Mar 21.
39 Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer. 2007 Oct 15;121(8):1697-704. doi: 10.1002/ijc.22867.
40 Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2562-71.
41 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
42 Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. Mol Immunol. 2015 Feb;63(2):521-9. doi: 10.1016/j.molimm.2014.10.008.
43 Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Apr;357(4):472-5. doi: 10.1007/pl00005195.
44 Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jun 11;287(1-2):57-64. doi: 10.1016/j.mce.2008.01.015. Epub 2008 Feb 3.
45 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
46 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
47 Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol. 2020 Oct;34(10):e22547. doi: 10.1002/jbt.22547. Epub 2020 Jun 26.
48 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
49 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
50 Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
51 Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
52 Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
53 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
54 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
55 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
56 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
57 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
58 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
59 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
60 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
61 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.